Common causes of extreme thrombocytosis differed in inpatient and outpatient settings, according to a review of 44,490 patient records.
A new risk stratification score for venous thromboembolism was developed and validated in a cohort of more than 4000 patients with multiple myeloma.
Eltrombopag and romiplostim demonstrated superior response compared with rituximab for persistent adult immune thrombocytopenia.
Rates of recurrence and bleeding were similar between the 3 treatments assessed, but rivaroxaban demonstrated lower mortality rates.
The American Society of Clinical Oncology released updates to their guidelines for thromboprophylaxis in patients with cancer.
Reinitiation of oral anticoagulant therapy may be warranted for some patients with atrial fibrillation who have a high risk of bleeding.
Researchers assessed whether loss of von Willebrand factor high-molecular-weight multimers was predictive of morbidity in thrombotic thrombocytopenic purpura.
Researchers interviewed clinicians and patients to develop a conceptual model of congenital thrombotic thrombocytopenic purpura.
New studies in morbidly obese patients suggest that direct oral anticoagulants may be a safe and efficacious treatment option for thromboembolism and atrial fibrillation.
Patients with secondary Evans syndrome demonstrated increased mortality compared with all other cohorts.
Incidences of recurrent thromboembolism and major bleeding did not significantly differ between patients receiving DOACs and patients receiving warfarin.
Combining caplacizumab with therapeutic plasma exchange could decrease hospital stays and treatment costs in the long term.
A higher proportion of black patients and female patients with thrombotic thrombocytopenic purpura had coexisting connective tissue disorders.
Researchers assessed incidence of recurrent thromboembolism and major bleeding in patients with cancer and incidental pulmonary embolism.
Current treatment strategies for immune thrombocytopenic purpura are centered on immunomodulation and decreasing platelet destruction
Continuing warfarin therapy for 18 months after an initial 6-month course decreased incidence of venous thrombosis and major bleeding.
The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 children.
Results of the study showed that the rate of symptomatic recurrent VTE – the primary end point – was similar in both treatment groups with 1.2% of patients experiencing a recurrent event in the rivaroxaban group compared with 3.0% in the standard anticoagulation group.
Utilizing a PLASMIC score-based algorithm may reduce treatment costs by reducing overutilization of therapeutic plasma exchange and expert consultations.
Therapeutic plasma exchange could become an effective mainstay of treatment for immune-mediated thrombotic thrombocytopenic purpura.
Rituximab treatment conferred short-term benefit against subsequent relapse, though this benefit decreased over time.
Similar rates of thrombotic events occurred in patients with FXII deficiency and unaffected controls.
Researchers described 2 patients with refractory thrombotic thrombocytopenic purpura who regained normal ADAMTS13 levels after splenectomy.
Platelet counts, ADAMTS13 recovery, and infective complications were not significantly different between the 2 treatment groups.
Researchers recommended performing lactate dehydrogenase level and blood smear testing in patients with renal and neurological symptoms.
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
Patients receiving caplacizumab experienced faster normalization of platelet count and fewer adverse events compared with patients on placebo.
Researchers conducted a meta-analysis of 9 studies in patients receiving either rituximab or conventional treatment for TTP.
Though all evaluated second-line treatments improved clinical outcomes, romiplostim was found to be the most effective at 6 months.
The VTE-BLEED risk score identified patients with pulmonary embolism at risk for in-hospital majorbleeding.
Among patients who underwent eculizumab withdrawal, 76.9% remained in remission during the course of the study.
The neural network developed in this study yielded a false-negative rate of 0.22%.
Although clinical trials are ongoing, the safety profile and net clinical benefit of DOACs for acute venous thromboembolism treatment are unclear.
Recent studies suggest that direct-acting oral anticoagulants may be a viable treatment option for cancer patients with VTE, but more research is needed.
Researchers reviewed outcomes from several phase 3 trials assessing the feasibility of fostamatinib for immune thrombocytopenia.
A French working group developed a treatment algorithm for diagnosis and treatment of neonatal thrombocytopenia of suspected or confirmed alloimmune origin.
Significantly fewer patients receiving apixaban experienced thromboembolism and major bleeding compared with patients receiving placebo.
An analysis of 2300 patients found similar prevalence of abdominal, pelvic, and thoracic cancer in patients with deep vein thrombosis and pulmonary embolism.
Current guidelines to diagnosis pulmonary embolism in pregnant patients offer conflicting recommendations.
Transgender women receiving hormone replacement therapy may be at an increased risk for thromboembolism, though data and recommendations vary across studies.
Patients receiving rivaroxaban did not experience a statistically significant decrease in thrombotic events compared with patients receiving placebo.
Researchers assessed potential risk factors for venous thromboembolism during pregnancy and postpartum in more than 100,000 Japanese women.
Thromboprophylactic treatment and serum albumin levels were not found to be associated with deep vein thrombosis incidence.
Because dysregulation of coagulation is a key feature of thromboinflammation, coagulation inhibitors may have therapeutic potential.
A 19-year-old woman presents with complaints of progressive shortness of breath, chest pain, and lower extremity edema over the past month.
Antifactor Xa activity after heparin spiking was lower in plasma samples from antithrombin-deficient patients compared with control samples.
First FDA-approved therapy specifically indicated for the treatment of aTTP
Researchers conducted the first real world study to compare the safety and effectiveness of apixaban and rivaroxaban in patients with VTE.
Researchers assessed the prevalence of various antiphosphatidylserine/prothrombin antibodies in patients with primary antiphospholipid syndrome.
Researchers attempted to identify the appropriate platelet count transfusion threshold in preterm infants with severe thrombocytopenia.
The interactions between von Willebrand factors and its cleaving protease ADAMTS-13 recently emerged as risk factors for pediatric thromboembolism.